DA
DNLI icon

Duality Advisers’s Denali Therapeutics DNLI Stock Holding History

Duality Advisers’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-19,728
Closed -$605K – 628
2022
Q3 		$605K Buy
+19,728
New +$641K 0.07% 389
2022
Q2 		– Sell
-34,200
Closed -$1.1M – 655
2022
Q1 		$1.1M Buy
+34,200
New +$1.18M 0.12% 300
2021
Q4 		– Sell
-23,045
Closed -$1.16M – 537
2021
Q3 		$1.16M Buy
+23,045
New +$1.3M 0.09% 323
2021
Q2 		– Sell
-19,642
Closed -$1.12M – 581
2021
Q1 		$1.12M Buy
+19,642
New +$1.31M 0.1% 328

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Duality Advisers's DNLI Position: Q4 2022 in Review

Duality Advisers sold out of Denali Therapeutics (DNLI) in Q4 2022, closing a stake of 19,728 shares — an estimated $605K sold.

Duality Advisers first reported a position in DNLI in Q1 2021 and held it in 4 quarters. The position peaked at $1.16M in Q3 2021. 197 funds tracked by Wall St. Rank hold DNLI as of Q4 2022.

  • Duality Advisers reported no remaining Denali Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Duality Advisers sold 19,728 Denali Therapeutics shares in Q4 2022, an estimated $605K.
  • Duality Advisers first reported a position in Denali Therapeutics in Q1 2021 and held it in 4 quarters.
  • Duality Advisers's Denali Therapeutics position peaked at $1.16M in Q3 2021.
  • 197 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2022.

Based on Duality Advisers's 13F filing for Q4 2022, filed 7 Feb 2023.